The trials performed worldwide toward noninvasive prenatal diagnosis (NIPD) of Down's syndrome (or trisomy 21) have shown the commercial and medical potential of NIPD compared to the currently used invasive prenatal diagnostic procedures. Extensive investigation of methylation differences between the mother and the fetus has led to the identification of differentially methylated regions (DMRs). In this study, we present a strategy using the methylated DNA immunoprecipitation (MeDiP) methodology in combination with real-time quantitative PCR (qPCR) to achieve fetal chromosome dosage assessment, which can be performed noninvasively through the analysis of fetal-specific DMRs. We achieved noninvasive prenatal detection of trisomy 21 by determining the methylation ratio of normal and trisomy 21 cases for each tested fetal-specific DMR present in maternal peripheral blood, followed by further statistical analysis. The application of this fetal-specific methylation ratio approach provided correct diagnosis of 14 trisomy 21 and 26 normal cases. Down's syndrome is considered to be the most frequent etiology of mental retardation, with an incidence of 1 in 700 child births in all popu lations worldwide 1 . Prenatal genetic diagnosis of trisomy 21 is currently performed using conventional cytogenetic or DNA analyses, which require fetal genetic material to be obtained by amniocentesis, chori onic villus sampling or cordocentesis. However, the above procedures are invasive and are associated with a considerable risk of fetal loss 1 . Therefore, there is a need for the development of NIPD strategies.
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Down's syndrome is considered to be the most frequent etiology of mental retardation, with an incidence of 1 in 700 child births in all popu lations worldwide 1 . Prenatal genetic diagnosis of trisomy 21 is currently performed using conventional cytogenetic or DNA analyses, which require fetal genetic material to be obtained by amniocentesis, chori onic villus sampling or cordocentesis. However, the above procedures are invasive and are associated with a considerable risk of fetal loss 1 . Therefore, there is a need for the development of NIPD strategies.
The discovery of free fetal DNA (ffDNA) in the maternal circulation during pregnancy 2 has made ffDNA a focus for alternative approaches toward the development of NIPD. Recently, ffDNA has been success fully used for the determination of fetal sex 3 and fetal Rh blood group status in maternal plasma 4, 5 . Nevertheless, direct analysis of the limited amount of ffDNA (3-6%) in the presence of excess of maternal DNA is a great challenge for the assessment of fetal chromosomal copy number 6 . Recent advances in this field have shown that ffDNA present in maternal circulation can be discriminated, enriched or both 7, 8 . One major development has been the investigation of DMRs between fetal DNA and maternal peripheral blood 8 . Serpin peptidase inhibitor clade B member 5 (SERPINB5) has been the first gene identified to be fetalspecific hypomethylated in maternal plasma 9 . A number of additional studies have focused on singlegene promoter regions 9, 10 or CpG islands on chromosome 21 (refs. 11-13) .
Current approaches developed using ffDNA for NIPD are subject to a number of limitations. The two main applications are the use of methylationsensitive restriction enzymes and the use of sodium bisulfite. In the first application, the requirement for DMRs contain ing a restriction site 11 limits the number of loci suitable for testing, whereas in the second application the bisulfite conversion leads to DNA degradation 14 . To overcome these limitations, we have recently used a newly developed technique called MeDiP 15, 16 to investigate the DNA methylation pattern of chromosomes 13, 18, 21, X and Y 16 . The MeDiP methodology uses an antibody specific for 5methylcytidine to capture methylated sites and therefore enrich for fetalspecific methylated DNA 17 .
We have selected a subset of DMRs on chromosome 21 and have applied the MeDiP methodology in combination with realtime qPCR in normal and trisomy 21 cases. To provide chromosome dosage infor mation, the ffDNA has to be hypermethylated compared to the maternal DNA. This is essential to achieve fetalspecific methylation enrichment, which is the key element in our study. We hypothesized that we would be able to discriminate normal from trisomy 21 cases by comparing the ratio values obtained from normal and trisomy 21 cases using fetalspecific methylated regions located on chromosome 21 (Fig. 1) . Furthermore, we hypothesized that a combination of DMRs, and not a single DMR, may be able to give an accurate NIPD of normal and trisomy 21 cases. The results have confirmed our initial hypotheses.
RESULTS

Fetal-specific DNA methylation ratio approach
To evaluate the efficiency of the MeDiP methodology, we tested a known hypermethylated (HYP1 13 ) region and a hypomethyl ated (U1 22 ) control region. We observed a hypermethylated status for the HYP1 13 region, with at least 315% higher values, and a hypomethylated status for the U1 22 1 We developed an approach for determining the DNA methylation ratio of 12 selected DMRs (EP1 to EP12) in 20 normal and 20 trisomy 21 cases (Fig. 1 and Supplementary Table 1) . We found that the majority of the ratio values in normal cases were at or below a value of 1, whereas in trisomy 21 cases the ratio values were above a value of 1 (Supplementary Table 1 ). For example, in the normal cases P6 and P13, the ratio values are at or below a value of 1 with the exception of EP10 in both cases and EP11 in case P13 (Fig. 2a) . The ratio values in the trisomy 21 cases P29 and P35 were above a value of 1 with the exception of EP9 in case P35 (Fig. 2b) .
Statistical analysis
In addition to the evaluation of the fetalspecific methylation ratio values, we proceeded with a detailed univariate statistical analysis that revealed the statistical significance of each of the 12 DMRs. To achieve this, we employed the MannWhitney U test, which esti mates the significance of each of the DMRs in terms of P values (Supplementary Table 2 ).
DMRs that can efficiently discriminate normal cases from trisomy 21 cases (P < 0.001), such as EP1, EP4, EP7 and EP10, showed a clear separation of the range of values obtained from normal cases com pared to the ones obtained from trisomy 21 cases (Fig. 3) . In contrast, DMRs that cannot discriminate efficiently normal cases from trisomy 21 cases (P > 0.05), such as EP8 and EP11, showed no clear separation between the normal and trisomy 21 cases, as the ratio values obtained from both normal and trisomy 21 cases were close to a value of 1 (Supplementary Table 1) .
Although a single DMR may not lead to the correct diagnosis of a normal or a trisomy 21 pregnancy with confidence, we hypothesized that a combination of DMRs may be able to achieve it. To test this, we used statistical tools that would generate the ideal combination of DMRs, which can give the highest possible diagnostic sensitivity and specificity. We concluded that the application of the socalled discri minant analysis provides a statistical approach that would accurately determine a normal or a trisomy 21 pregnancy.
The implementation of the discriminant analysis on 40 cases showed that eight out of 12 DMRs entered the final model of the prediction equation, and none was removed so that the stepwise analy sis consisted of eight steps in each of which a new predictor variable was chosen. The predictors were chosen in the following order according to the Wilks' Lambda statistic: EP4 (0.646), EP12 (0.456), EP6 (0.340), EP5 (0.251), EP7 (0.210), EP11 (0.159), EP10 (0.133) and EP8 (0.122) . The DMRs EP1, EP2, EP3 and EP9 were excluded from the model.
We then calculated the discriminant function coefficients for each of the DMRs. We used these values to construct the prediction equa tion, which can be used to classify cases. The resulting prediction equation is as follows: D = -6,331 + 0,959 X EP4 + 1,188 X EP5 + 0,424 X EP6 + 0,621 X EP7 + 0,028 X EP8 + 0,387 X EP10 -0,683 X EP11 + 0,897 X EP12 where X EPn = ratio value Sample; EPn , n = 1-12 and D is the discriminating value.
Classification of normal and trisomy 21 cases
We classified cases that give a D value above the cutting point as trisomy 21, whereas we classified those with values below the cut ting point as normal. As the two groups of cases are of equal size, the cutting point is 0. Hence, when D > 0, the case is classified as trisomy 21; when D ≤ 0 the case is classi fied as normal ( Table 1 and Supplementary  Table 3 ). Statistical evaluation of the diag nostic efficiency of the discriminant analysis function using the original validatory method Figure 1 Schematic illustration of the fetal-specific DNA methylation ratio approach. A fetus with trisomy 21 has an extra copy of the fetalspecific methylated region compared to a normal fetus. DNA methylation enrichment followed by real-time qPCR of a fetal-specific methylated region can allow relative quantification of the amount of fetal DNA in normal and trisomy 21 cases. showed a perfect classification for all normal and trisomy 21 cases, which correspond to 100% specificity and 100% sensitivity of the methodology. To enhance the capability of the resulting discrimi nating function, we checked whether all the assumptions were met (Supplementary Data).
We reevaluated the specificity and sensitivity of the methodology by performing a blind study consisting of 40 samples. The ratio values obtained from the eight selected DMRs (Supplementary Table 4) were applied to the prediction equation for each sample separately to calculate the D value. A total of 26 cases were classified as normal, whereas the remaining 14 were classified as trisomy 21 ( Table 2) . Crossreferencing with the samples' karyotypes confirmed the above findings (Supplementary Table 5) .
DISCUSSION
We hereby demonstrate that the application of MeDiP in combination with realtime qPCR using maternal peripheral blood permits non invasive prenatal detection of trisomy 21. The key enabling elements of this strategy are based on the direct assessment of fetal DNA within maternal circulation after methylation enrichment of fetalspecific methylated chromosome 21 regions. The employment of this method ology provided efficient enrichment of ffDNA in maternal circulation for the 80 cases (40 known and 40 blind) included in this study. The fetalspecific DNA methylation ratio approach and further statistical analysis showed that a combination of eight specific DMRs out of 12 enabled the correct diagnosis of all the cases.
Our results show a higher diagnostic sensitivity and specificity com pared to a previous study that used the RNASNP strategy (90% and 96.5%, respectively, in that study) 18 . The RNASNP study included only ten trisomy 21 cases in the range of 12-20 weeks old, with one tri somy 21 being incorrectly classified. In our study, a total number of 40 known (20 normal and 20 trisomy 21) and 40 blind samples (26 nor mal and 14 trisomy 21) from pregnancies of 11.1-14.4 weeks old were correctly classified providing 100% sensitivity and 100% specificity. Moreover, the diagnostic efficiency of our strategy is higher compared to currently applied firsttrimester screening protocols involving the use of nuchal translucency and biochemical markers 19, 20 .
Our approach involves the application of MeDiP and realtime qPCR, which are accessible in all basic diagnostic laboratories as they require no major and expensive infrastructure, are technically easier and of lower cost, conferring an additional advantage of our methodo logy in comparison to nextgeneration sequencing technologies, which are of high cost and not easily accessible to diagnostic labora tories [21] [22] [23] . Moreover, our approach is an improvement in compari son to the currently applied methodologies such as the use of sodium bisulfite conversion, of the DNA, which can cause up to 96% DNA degradation 14 and can complicate even further the quantification of limited amounts of ffDNA. Additionally, our diagnostic approach is not affected by fetal gender or the presence of informative poly morphic sites in contrast to previous studies using methods related to SNP analysis, fetalspecific RNA marker identification or epigenetic genetic ratio analysis 18, [24] [25] [26] [27] . This advantage is of high importance as the technology will be available to any pregnant woman. The approach described here has opened the way for NIPD of trisomy 21 to be potentially employed in the routine practice of all diagnostic laboratories and be applicable to all pregnancies. Such a noninvasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures. Furthermore, we speculate that this diagnostic strategy may prove advantageous in the future over the current biochemical screening methods for trisomy 21. Nevertheless, a largerscale study will need to be performed to assist the introduction of the diagnostic strategy into the clinical practice of prenatal diagnostic laboratories.
Finally, we speculate that evaluation and selection of DMRs from our previously generated microarray data 16 can be potentially used for NIPD of aneuploidies of chromosomes 13, 18, X and Y.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
ONLINE METhODS
Samples. For the purpose of the diagnostic strategy, we initially used 40 maternal peripheral blood samples with known karyotype (20 from normal pregnancies and 20 from trisomy 21 pregnancies) (Supplementary Table 5 ). Furthermore, we used 40 additional samples in a blinded fashion so that their identity and karyotype results were hidden from the investigator who carried out the test.
We collected 80 samples from 11.1-14.4 weeks of gestation in EDTA tubes and then stored them at −80 °C within 6 h of collection until further use. The experiments were approved by the Cyprus National Bioethics Committee. Informed consent was obtained from all participants.
Selection of DMRs. An indepth investigation of our previously identified DMRs 16 led us to select 12 DMRs (EP1-EP12) located on chromosome 21 for further investigation. EP8 and EP12 can be found in our previous study 16 . The 12 DMRs were selected on the basis of three criteria. First, they should have a hypermethylated status in placenta and hypomethylated status in peripheral blood to achieve fetalspecific DNA methylation enrichment and therefore increase the amount of ffDNA in maternal circulation. Second, they should have common methylation status between first and third trimester placentas to ensure the tissue specificity of the methylation status 16 . Finally, the level of differential methylation observed for these DMRs should be above the value of 1 in a logarithmic scale in at least one of the oligonucleotide probes included in the region 16 . Along with the 12 DMRs, we used two additional regions located on chromosomes 13 (HYP113) and 22 (U122) as hypermethylated and hypomethylated controls, respectively 15, 16 .
Application of MeDiP and real-time qPCR. We extracted DNA from 1 ml of each sample with the QIAamp DNA blood Midi kit (Qiagen). We then proceeded to immunoprecipitate methylated sites as described previously 16 . Briefly, we sheared by sonication 2.5 µg of DNA into fragments of approxi mately 300-1,000 base pairs in size. The fragmented DNA was blunt ended, and we added annealing linkers to both ends generated. We removed 50 ng of ligated DNA from each sample to be used as input genomic control DNA. We then applied the MeDiP methodology to the remaining ligated DNA samples (800 ng-1.2 µg) as described previously 16 . Finally, we performed ligationmediated PCR reactions using 10 ng of each input and immunopre cipitated DNA fraction with the aim to increase the amount of DNA.
We performed realtime qPCR reactions on all input and immuno precipitated fragments for the selected DMRs on chromosome 21 and the two control regions. The procedure followed for primer design and opti mization and the cycle conditions used have been described previously 16 (Supplementary Table 6 ).
Statistical analyses. We used the 40 samples with known karyotype to evalu ate the degree of discrimination of the 12 selected DMRs. To achieve this, we compared the fetalspecific methylation ratio values of the 20 normal cases to the ratio values of the 20 trisomy 21 cases for each of the 12 DMRs (Supplementary Table 1 and Supplementary Methods). In theory, the ratio of normal cases should be 1 and 1.5 for trisomy 21 cases. However, the observed ratios are usually of a smaller value for normal cases and of a higher value for trisomy 21 cases as a result of interindividual variability of the methylation levels 16 as well as the presence of maternal DNA background.
Further statistical analysis was essential to determine with accuracy the sta tistical significance of each DMR. To achieve this, we used the MannWhitney U test. This test is a nonparametric test for assessing whether two independent sets of observations come from the same distribution.
The final aim of our analysis was to correctly interpret the results of a case and accurately classify it as normal or trisomy 21. To achieve this, we applied the socalled discriminant analysis. The discriminant analysis can generate functions from a set of cases for which group membership is known. These functions can then be applied to new cases with measurements for the pre dictor variables but unknown group membership. We constructed a linear discriminant equation such that the two groups differ as much as possible on the function (Supplementary Methods).
We aimed to further validate our results by performing a blinded study. We used 40 blinded samples and tested the methylation enrichment of the eight selected DMRs. The ratio values obtained from each sample were applied to the prediction equation, and we determined their status (normal or trisomy 21).
Additional methods. Detailed methodology is described in the Supplementary Methods.
